99 results
Page 2 of 5
6-K
EX-99.1
4afbvh3h
7 Sep 23
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
4:01pm
6-K
EX-1.1
r983t5 x4p3ga
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
6-K
EX-99.1
oa7dr10c
17 Jul 23
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
8:00am
6-K
EX-99.1
qre9s eg1bybtct98
30 Jun 23
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
4:10pm
6-K
EX-99.1
hm0g n9otq
21 Jun 23
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
9:08am
6-K
EX-99.1
07zo0f 9pm4em
2 Jun 23
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
9:04am
6-K
EX-99.1
736lw3w 4d
16 May 23
At-The-Market Issuance Sales Agreement
8:06pm
6-K
EX-99.1
jnr8qq0jtf8ddmfej6rq
2 May 23
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer’s Disease and Agitation
7:28am
6-K
EX-99.1
lc91dv83jba
4 Apr 23
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
5:48pm
6-K
EX-99.2
2hk0z4fm71
29 Dec 22
Interim Consolidated Financial Statements
4:03pm
6-K
EX-99.1
raxql9f7 lr1
8 Nov 22
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
7:33am
6-K
EX-99.3
5xdl7zump i43j
30 Sep 22
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
7:27am
6-K
EX-99.1
b8xft52l4kfufc yl
11 Aug 22
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
8:42am
6-K
EX-99.1
h72hhj
2 Aug 22
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
4:00pm
6-K
EX-99.1
ri5gj
29 Jun 22
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
8:36am
6-K
EX-99.1
jo3002f
24 Jun 22
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
8:52am
6-K
EX-99.1
xhsyr
1 Jun 22
SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
4:11pm
6-K
EX-99.2
jh0kdm1g zev
27 May 22
SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
4:10pm
6-K
EX-99.1
1gtu57b85h
26 May 22
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome
8:33am